An Israeli bio pharmaceutical company said that it has the resources to produce ZMapp – the drug that can potentially cure Ebola.
The death toll from the Ebola epidemic has climbed above 2,000, the World Health Organisation (WHO) said Friday, as it voiced hopes a vaccine could be available in November.
However, supplies of experimental medicines — including the prototype drug ZMapp — are limited, and “will not be sufficient for several months to come,” the World Health Organisation (WHO) warned Friday.
Protalix, an Israeli bio pharmaceutical company, said that it has the resources to produce the coveted ZMapp, which has recently run out, Israeli site The Times of Israel, citing Channel 2 TV‘s report, said Sunday.
The death toll from the Ebola epidemic has climbed above 2,000, the World Health Organisation (WHO) said Friday, as it voiced hopes a vaccine could be available in November.
However, supplies of experimental medicines — including the prototype drug ZMapp — are limited, and “will not be sufficient for several months to come,” the World Health Organisation (WHO) warned Friday.
Protalix, an Israeli bio pharmaceutical company, said that it has the resources to produce the coveted ZMapp, which has recently run out, Israeli site The Times of Israel, citing Channel 2 TV‘s report, said Sunday.